• 1
    Garovic VD, Hayman SR. Hypertension in pregnancy: an emerging risk factor for cardiovascular disease. Nat Clin Pract Nephrol. 2007;3:613622.
  • 2
    Hutcheon JA, Lisonkova S, Joseph KS. Epidemiology of pre-eclampsia and the other hypertensive disorders of pregnancy. Best Pract Res Clin Obstet Gynaecol. 2011;25:391403.
  • 3
    Report of the national high blood pressure education program working group on high blood pressure in pregnancy. Am J Obstet Gynecol. 2000;183:S1S22.
  • 4
    Granger JP, Alexander BT, Llinas MT, et al. Pathophysiology of hypertension during preeclampsia linking placental ischemia with endothelial dysfunction. Hypertension. 2001;38(3 Pt 2):718722.
  • 5
    Roberts JM, Taylor RN, Musci TJ, et al. Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol. 1989;161:12001204.
  • 6
    Garovic VB, Bailey KR, Boerwinkle E, et al. Hypertension in pregnancy is associated with elevated C-reactive protein levels later in life . Pregnancy Hypertens. 2010;(suppl 1):S1S41.
  • 7
    Garovic VD, Bailey KR, Boerwinkle E, et al. Hypertension in pregnancy as a risk factor for cardiovascular disease later in life. J Hypertens. 2010;28:826833.
  • 8
    Bar J, Kaplan B, Wittenberg C, et al. Microalbuminuria after pregnancy complicated by pre-eclampsia. Nephrol Dial Transplant. 1999;14:11291132.
  • 9
    Nisell H, Lintu H, Lunell NO, et al. Blood pressure and renal function seven years after pregnancy complicated by hypertension. Br J Obstet Gynaecol. 1995;102:876881.
  • 10
    Hillege HL, Fidler V, Diercks GF, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation. 2002;106:17771782.
  • 11
    Verhave JC, Gansevoort RT, Hillege HL, et al. An elevated urinary albumin excretion predicts de novo development of renal function impairment in the general population. Kidney Int Suppl. 2004;92:S18S21.
  • 12
    Ruggenenti P, Perna A, Mosconi L, et al. Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. “Gruppo Italiano di Studi Epidemiologici in Nefrologia” (GISEN). Kidney Int. 1998;53:12091216.
  • 13
    McDonald SD, Han Z, Walsh MW, et al. Kidney disease after preeclampsia: a systematic review and meta-analysis. Am J Kidney Dis. 2010;55:10261039.
  • 14
    FBPP Investigators. Multi-center genetic study of hypertension: the Family Blood Pressure Program (FBPP). Hypertension. 2002;39:39.
  • 15
    Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604612.
  • 16
    Mattix HJ, Hsu CY, Shaykevich S, Curhan G. Use of the albumin/creatinine ratio to detect microalbuminuria: implications of sex and race. J Am Soc Nephrol. 2002;13:10341039.
  • 17
    Sabatine MS, Morrow DA, Jablonski KA, et al. Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. Circulation. 2007;115:15281536.
  • 18
    Diehl CL, Brost BC, Hogan MC, et al. Preeclampsia as a risk factor for cardiovascular disease later in life: validation of a preeclampsia questionnaire. Am J Obstet Gynecol. 2008;198:e11e13.
  • 19
    Tracy RP, Lemaitre RN, Psaty BM, et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol. 1997;17:11211127.
  • 20
    North RA, Simmons D, Barnfather D, Upjohn M. What happens to women with preeclampsia? Microalbuminuria and hypertension following preeclampsia Aust N Z J Obstet Gynaecol. 1996;36:233238.
  • 21
    Jacquemyn Y, Jochems L, Duiker E, et al. Long-term renal function after HELLP syndrome. Gynecol Obstet Invest. 2004;57:117120.
  • 22
    Lampinen KH, Ronnback M, Groop PH, Kaaja RJ. Renal and vascular function in women with previous preeclampsia: a comparison of low- and high-degree proteinuria. Kidney Int. 2006;70:18181822.
  • 23
    Viberti GC, Vergani D. Detection of potentially reversible diabetic albuminuria. A three-drop agglutination test for urinary albumin at low concentration. Diabetes. 1982;31:973975.
  • 24
    van der Velde M, Halbesma N, de Charro FT, et al. Screening for albuminuria identifies individuals at increased renal risk. J Am Soc Nephrol. 2009;20:852862.
  • 25
    Iseki K, Kinjo K, Iseki C, Takishita S. Relationship between predicted creatinine clearance and proteinuria and the risk of developing ESRD in Okinawa, Japan. Am J Kidney Dis. 2004;44:806814.
  • 26
    Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, et al. Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia. 1989;32:219226.
  • 27
    Papaioannou GI, Seip RL, Grey NJ, et al. Brachial artery reactivity in asymptomatic patients with type 2 diabetes mellitus and microalbuminuria (from the Detection of Ischemia in Asymptomatic Diabetics-brachial artery reactivity study). Am J Cardiol. 2004;94:294299.
  • 28
    Yokoyama H, Sone H, Saito K, et al. Flow-mediated dilation is associated with microalbuminuria independent of cardiovascular risk factors in type 2 diabetes – interrelations with arterial thickness and stiffness. J Atheroscler Thromb. 2011;18:744752.
  • 29
    Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286:421426.
  • 30
    Smink PA, Lambers Heerspink HJ, Gansevoort RT, et al. Albuminuria, estimated GFR, traditional risk factors, and incident cardiovascular disease: the PREVEND (Prevention of Renal and Vascular Endstage Disease) Study. Am J Kidney Dis. 2012;60:804811.
  • 31
    Odutayo A, Hladunewich M. Obstetric nephrology: renal hemodynamic and metabolic physiology in normal pregnancy. Clin J Am Soc Nephrol. 2012;7:20732080.
  • 32
    Palatini P, Mormino P, Dorigatti F, et al. Glomerular hyperfiltration predicts the development of microalbuminuria in stage 1 hypertension: the HARVEST. Kidney Int. 2006;70:578584.
  • 33
    Sou SC, Chen WJ, Hsieh WS, Jeng SF. Severe obstetric complications and birth characteristics in preterm or term delivery were accurately recalled by mothers. J Clin Epidemiol. 2006;59:429435.
  • 34
    Mosca L, Benjamin EJ, Berra K, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women–2011 update: a guideline from the American Heart Association. J Am Coll Cardiol. 2011;57:14041423.
  • 35
    Atthobari J, Asselbergs FW, Boersma C, et al. Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: a pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT). Clin Ther. 2006;28:432444.
  • 36
    Boersma C, Gansevoort RT, Pechlivanoglou P, et al. Screen-and-treat strategies for albuminuria to prevent cardiovascular and renal disease: cost-effectiveness of nationwide and targeted interventions based on analysis of cohort data from the Netherlands. Clin Ther. 2010;32:11031121.